Skip to Content

Trial of Antibody Drug for COVID-19 Stopped for Lack of Effectiveness

TUESDAY, Oct. 27, 2020 -- Testing of the Eli Lilly antibody drug for hospitalized COVID-19 patients has been halted because the treatment does not help them recover from their infection.

Two weeks ago, enrollment in the study was paused because of a possible safety issue, theAssociated Pressreported. But the U.S. National Institute of Allergy and Infectious Diseases, which sponsored the Lilly study, pulled the plug on the trial Monday -- not because of any safety problem, but because there was only a slight chance that the drug would be effective.

Although it is a setback for one of the most promising treatment approaches for COVID-19, Lilly said in a statement that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients to try to prevent hospitalization and severe illness, theAPsaid.Lilly and Regeneron have both asked for emergency use authorization from the U.S. Food and Drug Administration while late-stage studies continue. Lilly said Monday that its request is based on other results suggesting that the drug helps patients who are not hospitalized and that it will continue to seek FDA permission for emergency use, the AP reported.

AP News Article 1
AP News Article 2

© 2021 HealthDay. All rights reserved.

Posted: October 2020

Read this next

Physician's Briefing Weekly Coronavirus Roundup

Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 19 to 22, 2021. This roundup...

Adults Delaying Even Emergency Care During COVID-19

FRIDAY, Jan. 22, 2021 -- Two-thirds of Americans are concerned about going to medical appointments even for an emergency when COVID-19 rates are high in their area, according to...

Antibody Drug May Protect Nursing Home Residents, Staff From COVID-19

FRIDAY, Jan. 22, 2021 -- An antibody drug that has emergency use authorization from the U.S. Food and Drug Administration for use in early-stage COVID-19 patients with symptoms...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.